Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth

Kamada outlined a growth strategy centered on rising demand for specialty plasma-derived therapies, supported by product sales, distribution agreements and plasma-supply initiatives. The company also identified potential acquisitions as an expansion avenue, though the presentation disclosed no specific financial targets, transaction terms or near-term earnings catalyst.